Parabilis Medicines: Why Ra Capital Keeps Buying $5B Bet
Parabilis Medicines, valued at $5 billion with zero revenue, posted a -772.6% EPS miss in its first public quarter. Yet Ra Capital, which anchored the IPO at $20, kept buying above $27, signaling conv
Ra Capital Keeps Buying PBLS Despite $5B Zero-Revenue Bet
NEW YORK, September 6 —
Parabilis Medicines, Inc. (PBLS) posted a -772.6% EPS miss in its first public quarter (-$2.12 actual versus a -$0.24 consensus estimate) on zero trailing revenue, yet Ra Capital Management, which anchored the June IPO with a $394.57 million purchase at $20.00, kept buying in the open market above $27 in late July. The stock now trades at $40.42.
- Q2 EPS -$2.12 vs. -$0.24 consensus; -772.6% miss; zero trailing revenue, per the August 8-K
- Ra Capital added shares at $27-$30 in late July; ICONIQ Capital opened a $9.58M position
- Cash $1.12B vs. $0.05B total debt; operating cash outflow -$111M trailing
A Miss That Was Never the Point
Parabilis Medicines, founded in 2015 in Cambridge, Massachusetts, has no commercial products. Its Helicon platform engineers stabilized helical peptides targeting intracellular protein-protein interactions, a category traditional small molecules cannot reach. FOG-001, the lead program, blocks beta-catenin's interaction with TCF transcription factors in cancer cells. A 145-person organization burning $111 million annually is priced on the probability that a class of drugs nobody has successfully built yet will work, not on current earnings. With $1.12 billion in cash against $0.05 billion in debt, the runway is long enough that burn rate, for now, is the least interesting number on the sheet.
Ra Capital's Second Conviction
The accumulation pattern tells a specific story. Ra Capital Management purchased 19,728,353 shares at $20.00 on June 11, committing $394.57 million at the IPO. Then, as PBLS rose into the $27.13-$30.00 range in late July, Ra kept adding in the open market, paying 35% to 50% above its own entry price to increase a position it already dominated. ICONIQ Capital has since opened a $9.58 million position. With 81.8% institutional ownership and short interest at only 4.3% of float, the skeptic trade is structurally thin. Whether Ra's escalating commitment reflects proprietary insight into FOG-001 trial progress or a structural view on beta-catenin biology, the buying is deliberate and disclosed.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PBLS | $5.0B | n/a | +27.9% |
| KLRA | $2.1B | n/a | -37.6% |
| COAG | $2.1B | n/a | +30.6% |
| EIKN | $588M | n/a | -27.6% |
| AVLN | $1.7B | n/a | +26.8% |
| MANE | $4.1B | n/a | +161.0% |
What FOG-001 Data Has to Prove
The consensus price target of $41.75 sits $1.33 above PBLS's current level, implying street models have essentially priced in whatever is publicly knowable. The real variable is FOG-001 clinical data: a positive readout in beta-catenin-driven tumors would justify a re-rating well above $41.75; a null result would put Ra Capital's IPO stake to the test. At $40.42 against a $4.99 billion market cap with no revenue, the stock already prices a clinical outcome that has not been announced. Run the free Parabilis Medicines, Inc. deep-dive → for the latest fundamentals, or use the DCF calculator to model what revenue assumptions underpin a $5 billion pre-revenue valuation.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What is Parabilis Medicines FOG-001?
FOG-001 blocks beta-catenin's interaction with TCF transcription factors in cancer cells. It's part of the Helicon platform, which engineers stabilized helical peptides targeting intracellular protein-protein interactions, a category traditional small molecules cannot reach.
Why did Ra Capital keep buying Parabilis stock?
Ra Capital purchased shares at $20 during the June IPO, then kept adding at $27-$30 in the open market, paying 35% to 50% above its entry price. The pattern points to either proprietary insight into FOG-001 trial progress or conviction on beta-catenin biology as a drug target.
How much cash does Parabilis have?
Parabilis has $1.12 billion in cash against $0.05 billion in debt, with a burn rate of $111 million annually. That runway makes financial health the least pressing valuation variable for now.
What was Parabilis' earnings miss?
Parabilis posted a -772.6% EPS miss (-$2.12 vs. -$0.24 consensus) with zero trailing revenue. As a pre-commercial biotech, the company is valued on clinical trial probability, not current earnings power.
Is Parabilis Medicines overvalued?
At $40.42 against a $4.99 billion market cap with no revenue, Parabilis prices in a clinical outcome that has not yet been announced. The consensus price target of $41.75 suggests street models have essentially priced in whatever is publicly knowable, with FOG-001 clinical data as the real remaining variable.
Parabilis Medicines carries a $4.99 billion market cap with zero trailing revenue and a Q2 EPS miss of -772.6% — yet Ra Capital Management, which led a $394.57 million purchase at the $20 IPO price in June, continued buying shares above $30 in July, and ICONIQ Capital has since opened a fresh $9.58 million position. The market is pricing a clinical outcome for FOG-001 that has not yet been disclosed.